Skye Bioscience Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Skye Bioscience disminuyan en un 36.1% al año. Se prevé que el BPA disminuya en un 28.7% al año.

Información clave

-36.1%

Tasa de crecimiento de los beneficios

-28.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	08 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:SKYE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-52	-47	-33	4
12/31/2025	N/A	-41	-21	-26	6
12/31/2024	N/A	-29	-25	-22	6
9/30/2024	N/A	-21	-22	-21	N/A
6/30/2024	N/A	-42	-20	-20	N/A
3/31/2024	N/A	-37	-15	-15	N/A
12/31/2023	N/A	-38	-14	-14	N/A
9/30/2023	N/A	-43	-15	-15	N/A
6/30/2023	N/A	-21	-13	-13	N/A
3/31/2023	N/A	-22	-14	-14	N/A
12/31/2022	N/A	-19	-13	-13	N/A
9/30/2022	N/A	-12	-10	-10	N/A
6/30/2022	N/A	-11	-9	-9	N/A
3/31/2022	N/A	-9	-8	-8	N/A
12/31/2021	N/A	-9	-7	-6	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-7	-7	-7	N/A
3/31/2021	N/A	-6	-6	-6	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	0	-6	-6	N/A
6/30/2020	N/A	-4	-5	-5	N/A
3/31/2020	N/A	13	-6	-6	N/A
12/31/2019	N/A	1	-6	-6	N/A
9/30/2019	N/A	-10	-6	-6	N/A
6/30/2019	N/A	-7	-5	-5	N/A
3/31/2019	N/A	-26	-4	-4	N/A
12/31/2018	N/A	-19	-4	-4	N/A
9/30/2018	N/A	-14	-5	-5	N/A
6/30/2018	N/A	-12	N/A	-4	N/A
3/31/2018	N/A	-10	N/A	-4	N/A
12/31/2017	N/A	-4	N/A	-3	N/A
9/30/2017	N/A	-5	N/A	-2	N/A
6/30/2017	N/A	-5	N/A	-2	N/A
3/31/2017	N/A	-4	N/A	-3	N/A
12/31/2016	N/A	-4	N/A	-4	N/A
9/30/2016	N/A	-3	N/A	-4	N/A
6/30/2016	N/A	-3	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-4	N/A
12/31/2015	N/A	-5	N/A	-4	N/A
9/30/2015	N/A	-6	N/A	-3	N/A
6/30/2015	N/A	-6	N/A	-3	N/A
3/31/2015	N/A	-4	N/A	-3	N/A
12/31/2014	N/A	-3	N/A	-2	N/A
9/30/2014	N/A	-1	N/A	-1	N/A
6/30/2014	N/A	0	N/A	0	N/A
3/31/2014	N/A	0	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SKYE siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que SKYE siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que SKYE siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de SKYE crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que SKYE no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SKYE se prevé que sea elevada dentro de 3 años.

Skye Bioscience Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento